Sarepta Therapeutics, Inc. (NASDAQ:SRPT) had its price target lowered by stock analysts at JMP Securities to $48.00 in a research note issued on Wednesday. JMP Securities’ price objective would indicate a potential upside of 39.58% from the company’s previous close. A number of other research analysts have also recently weighed in on SRPT. Royal Bank […]
